Navigation Links
Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
Date:5/10/2010

SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Ninth Annual JMP Securities Research Conference.  The details are as follows:  

Date:  May 12, 2010

Time:  8:30am Pacific Time

Location: The Ritz-Carlton, San Francisco

Speaker: Michael Narachi, Chief Executive Officer

A live webcast of the presentation can be accessed in the investor relations section of the Orexigen website at http://www.orexigen.com, and will be available for 14 days following the presentation.  Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has submitted an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference
2. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
3. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
6. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
7. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
8. Orexigen(R) Therapeutics to Present at Upcoming Meetings
9. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
10. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... Charm Sciences, Inc. is pleased to announce the Charm® ROSA® Tetracycline-SL ... Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a drug residue test kit ... NCIMS voted at its annual meeting in April, 2015 to establish a pilot program ...
(Date:7/20/2017)... Irvine, Calif. (PRWEB) , ... July 20, 2017 ... ... James G. Fujimoto, Ph.D ., the Elihu Thomson Professor of Electrical Engineering ... Beckman-Argyros Vision Research Award winner. Presented annually, the award recognizes an individual ...
(Date:7/20/2017)... AR (PRWEB) , ... July 20, 2017 , ... ... Rogers is joining the company’s board of directors. This addition continues to strengthen ... board," said Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... clinical trial sites and study participants truly unified. TrialKit, a native mobile app, ... CFR Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):